Substitute PTO/SB/08A (07-05)

Approved for use through 07/31/2006 Substitute for form 1449A/PTO Complete if Known (Modified) 10/804,762 Application Number INFORMATION DISCLOSURE 03/19/2004 STATEMENT BY APPLICANT Qi. Yan First Named Inventor 1633 Art Unit (use as many sheets as necessary) Examiner Name KELLY, Robert Sheet 1 1 Attorney Docket Number Docket A-71826 (471702-00005)

	U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	US-	****		
	A2	US-			
	A3	US-			
	A4	US-			
	A5	US-			
	A6	US-			
	A7	US-			
	A8	US-			
	A9	US-			
	A10	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ² Number ⁴ Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYYY	Name of Patentee or Applicant of Cited Document .	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁰
	B1					

		NON PATENT LITERATURE DOCUMENTS		Ĺ
Examiner Initials*	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), (title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	ĺ
		CHOKSI, S., et al. "A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple		L
	0,	Transplant. (2004) 10: 669-80.	-	Γ
	C2	KERN, P., et al. "Expression, purification, and functional analysis of murine ectodemain fragments of CD8αα and CD8αβ dimeres." J. Biol. Chem. (1999) 274: 2737-43;		
	C2	SEWELL, AK, et al. "Antagonism of cytotoxic T-lymphocyte activation by soluble CD8." Net. Med.		-
		(1999) 5: 399-404;		

Examiner Signature	/Robert Kelly/ (05/06/2008)	Date Considered	05/06/2008			
FYAMINED 4 Throughout the state of the state						

*EXAMINER. † These references were previously cited in a related application relied upon for an earlier filling date under 35 USC 120 and no copies are submitted in accordance with 37 CFR 1.98(d). Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through submitted in accordance with 37 CFK 154(0), insite in reservoire consistency, whereir or not case in an optionalization where you because it is not contained to the contained t

Applicant is to place a check mark here if English Language Translation is attached. 16 if possible.

This collection of information is required by 37 CFR 197 and 19.8. The information is required to botain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.